Evommune EVMN
NYSE EVMN
$8.62 +0.76 (+9.67%)
At close: Nov 11, 2026 · 4:00 PM EST

Evommune (EVMN) Return on Sales [ROS] (2025 - 2026)

Updated

Evommune (EVMN) posted Return on Sales [ROS] of -1018.93% for Q2 2026, down 119.01 percentage points from the prior quarter.

Analysis

Evommune (EVMN) Return on Sales [ROS] (2025 - 2026) Analysis & Trends

For FY2025, Evommune's Return on Sales [ROS] came in at -623.62%, up 376.56 percentage points from FY2024.

  • In prior years, Evommune's Return on Sales [ROS] was -1000.19% in FY2024.
  • According to Business Quant data, Return on Sales [ROS] for the three prior quarters was -899.92% (Q1 2026), -623.62% (Q4 2025) and -133.28% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 Evommune 285.17 Mn -352.34 Mn - -1,018.93%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -1,018.93%
Mar 31, 2026 -899.92%
Dec 31, 2025 -623.62%
Sep 30, 2025 -133.28%
Mar 31, 2025 -501.07%
API Access

Evommune Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=EVMN&period=max&api_key=YOUR_API_KEY